Development and Evaluation of a Mobile App Designed to Increase HIV Testing and Pre-exposure Prophylaxis Use Among Young Men Who Have Sex With Men in the United States: Open Pilot Trial.
HIV
mHealth
men who have sex with men
mobile apps
mobile phone
pilot study
pre-exposure prophylaxis
Journal
Journal of medical Internet research
ISSN: 1438-8871
Titre abrégé: J Med Internet Res
Pays: Canada
ID NLM: 100959882
Informations de publication
Date de publication:
24 03 2021
24 03 2021
Historique:
received:
22
10
2020
accepted:
08
02
2021
revised:
11
12
2020
entrez:
24
3
2021
pubmed:
25
3
2021
medline:
21
9
2021
Statut:
epublish
Résumé
HIV disproportionately affects young men who have sex with men (YMSM) in the United States. Uptake of evidence-based prevention strategies, including routine HIV testing and use of pre-exposure prophylaxis (PrEP), is suboptimal in this population. Novel methods for reaching YMSM are required. The aim of this study is to describe the development and evaluate the feasibility and acceptability of the MyChoices app, a mobile app designed to increase HIV testing and PrEP use among YMSM in the United States. Informed by the social cognitive theory, the MyChoices app was developed using an iterative process to increase HIV testing and PrEP uptake among YMSM. In 2017, beta theater testing was conducted in two US cities to garner feedback (n=4 groups; n=28 YMSM). These findings were used to refine MyChoices, which was then tested for initial acceptability and usability in a technical pilot (N=11 YMSM). Baseline and 2-month postbaseline assessments and exit interviews were completed. Transcripts were coded using a deductive approach, and thematic analysis was used to synthesize data; app acceptability and use data were also reported. The MyChoices app includes personalized recommendations for HIV testing frequency and PrEP use; information on types of HIV tests and PrEP; ability to search for nearby HIV testing and PrEP care sites; and ability to order free home HIV and sexually transmitted infection test kits, condoms, and lube. In theater testing, YMSM described that MyChoices appears useful and that they would recommend it to peers. Participants liked the look and feel of the app and believed that the ability to search for and be pinged when near an HIV testing site would be beneficial. Some suggested that portions of the app felt repetitive and preferred using casual language rather than formal or medicalized terms. Following theater testing, the MyChoices app was refined, and participants in the technical pilot used the app, on average, 8 (SD 5.0; range 2-18) times over 2 months, with an average duration of 28 (SD 38.9) minutes per session. At the 2-month follow-up, the mean System Usability Scale (0-100) score was 71 (ie, above average; SD 11.8). Over 80% (9/11) of the participants reported that MyChoices was useful and 91% (10/11) said that they would recommend it to a friend. In exit interviews, there was a high level of acceptability for the content, interface, and features. These data show the initial acceptability and user engagement of the MyChoices app. If future studies demonstrate efficacy in increasing HIV testing and PrEP uptake, the app is scalable to reach YMSM across the United States. Clinicaltrials.gov NCT03179319; https://clinicaltrials.gov/ct2/show/NCT03179319. RR2-10.2196/10694.
Sections du résumé
BACKGROUND
HIV disproportionately affects young men who have sex with men (YMSM) in the United States. Uptake of evidence-based prevention strategies, including routine HIV testing and use of pre-exposure prophylaxis (PrEP), is suboptimal in this population. Novel methods for reaching YMSM are required.
OBJECTIVE
The aim of this study is to describe the development and evaluate the feasibility and acceptability of the MyChoices app, a mobile app designed to increase HIV testing and PrEP use among YMSM in the United States.
METHODS
Informed by the social cognitive theory, the MyChoices app was developed using an iterative process to increase HIV testing and PrEP uptake among YMSM. In 2017, beta theater testing was conducted in two US cities to garner feedback (n=4 groups; n=28 YMSM). These findings were used to refine MyChoices, which was then tested for initial acceptability and usability in a technical pilot (N=11 YMSM). Baseline and 2-month postbaseline assessments and exit interviews were completed. Transcripts were coded using a deductive approach, and thematic analysis was used to synthesize data; app acceptability and use data were also reported.
RESULTS
The MyChoices app includes personalized recommendations for HIV testing frequency and PrEP use; information on types of HIV tests and PrEP; ability to search for nearby HIV testing and PrEP care sites; and ability to order free home HIV and sexually transmitted infection test kits, condoms, and lube. In theater testing, YMSM described that MyChoices appears useful and that they would recommend it to peers. Participants liked the look and feel of the app and believed that the ability to search for and be pinged when near an HIV testing site would be beneficial. Some suggested that portions of the app felt repetitive and preferred using casual language rather than formal or medicalized terms. Following theater testing, the MyChoices app was refined, and participants in the technical pilot used the app, on average, 8 (SD 5.0; range 2-18) times over 2 months, with an average duration of 28 (SD 38.9) minutes per session. At the 2-month follow-up, the mean System Usability Scale (0-100) score was 71 (ie, above average; SD 11.8). Over 80% (9/11) of the participants reported that MyChoices was useful and 91% (10/11) said that they would recommend it to a friend. In exit interviews, there was a high level of acceptability for the content, interface, and features.
CONCLUSIONS
These data show the initial acceptability and user engagement of the MyChoices app. If future studies demonstrate efficacy in increasing HIV testing and PrEP uptake, the app is scalable to reach YMSM across the United States.
TRIAL REGISTRATION
Clinicaltrials.gov NCT03179319; https://clinicaltrials.gov/ct2/show/NCT03179319.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
RR2-10.2196/10694.
Identifiants
pubmed: 33759792
pii: v23i3e25107
doi: 10.2196/25107
pmc: PMC8074990
doi:
Banques de données
ClinicalTrials.gov
['NCT03179319']
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25107Subventions
Organisme : NIAID NIH HHS
ID : P30 AI050409
Pays : United States
Organisme : NICHD NIH HHS
ID : U01 HD068040
Pays : United States
Organisme : NICHD NIH HHS
ID : U19 HD089881
Pays : United States
Informations de copyright
©Katie B Biello, Jonathan Hill-Rorie, Pablo K Valente, Donna Futterman, Patrick S Sullivan, Lisa Hightow-Weidman, Kathryn Muessig, Julian Dormitzer, Matthew J Mimiaga, Kenneth H Mayer. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 24.03.2021.
Références
MMWR Morb Mortal Wkly Rep. 2017 Aug 11;66(31):830-832
pubmed: 28796758
N Engl J Med. 2010 Dec 30;363(27):2587-99
pubmed: 21091279
PLoS One. 2012;7(3):e33119
pubmed: 22470438
Curr HIV/AIDS Rep. 2019 Feb;16(1):120-128
pubmed: 30707399
AIDS Patient Care STDS. 2013 Mar;27(3):181-90
pubmed: 23442029
J Int AIDS Soc. 2019 Feb;22(2):e25252
pubmed: 30775846
Arch Sex Behav. 2018 Oct;47(7):2101-2107
pubmed: 28929260
Psychol Serv. 2019 May;16(2):255-259
pubmed: 30407059
AIDS Patient Care STDS. 2016 Jun;30(6):254-60
pubmed: 27214751
Clin Psychol Sci. 2014 Jan 1;2(1):22-34
pubmed: 25821658
Soc Sci Med. 2005 Apr;60(7):1467-78
pubmed: 15652680
Subst Use Misuse. 2010 Apr;45(5):648-70
pubmed: 20222777
JMIR Mhealth Uhealth. 2017 Mar 09;5(3):e26
pubmed: 28279949
AIDS Behav. 2019 Oct;23(10):2803-2815
pubmed: 31407211
Hum Vaccin Immunother. 2019;15(7-8):1815-1823
pubmed: 30625049
Curr HIV/AIDS Rep. 2018 Aug;15(4):336-349
pubmed: 29959649
Clin Infect Dis. 2020 Jul 27;71(3):574-582
pubmed: 31499518
AIDS. 2015 Sep 10;29(14):1855-62
pubmed: 26372391
J Med Internet Res. 2017 Jun 19;19(6):e218
pubmed: 28630033
J Acquir Immune Defic Syndr. 2020 May 1;84(1):92-100
pubmed: 32267659
J Adolesc Health. 2012 Sep;51(3):207-12
pubmed: 22921129
BMJ. 2015 Mar 03;350:h1099
pubmed: 25736806
AIDS Patient Care STDS. 2013 Apr;27(4):211-22
pubmed: 23565925
JMIR Public Health Surveill. 2015 Nov 16;1(2):e18
pubmed: 27227136
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):21-29
pubmed: 27632233
JMIR Res Protoc. 2018 Aug 03;7(8):e10365
pubmed: 30076126
Am J Public Health. 2018 Oct;108(10):1408-1417
pubmed: 30138062
Am J Public Health. 2008 Jun;98(6):1059-67
pubmed: 18445804
Health Educ Behav. 2004 Apr;31(2):143-64
pubmed: 15090118
JMIR Mhealth Uhealth. 2017 Apr 13;5(4):e46
pubmed: 28408360
JMIR Mhealth Uhealth. 2014 Oct 29;2(4):e47
pubmed: 25355249
Am J Community Psychol. 2016 Mar;57(1-2):144-57
pubmed: 27217318
J Int AIDS Soc. 2016 Sep 23;19(1):20791
pubmed: 27665722
Curr HIV/AIDS Rep. 2015 Mar;12(1):173-90
pubmed: 25626718
AIDS Patient Care STDS. 2014 Mar;28(3):128-35
pubmed: 24601734
J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):62-69
pubmed: 29771790
J Psychiatr Res. 2011 May;45(5):626-9
pubmed: 21035130
Open AIDS J. 2013 Aug 13;7:17-41
pubmed: 24133558
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
JAMA. 2019 Jun 18;321(23):2326-2336
pubmed: 31184701
MMWR Morb Mortal Wkly Rep. 2018 Oct 19;67(41):1147-1150
pubmed: 30335734
JAMA. 2019 Jun 11;321(22):2203-2213
pubmed: 31184747
J Infect Dis. 2016 Mar 1;213(5):776-83
pubmed: 26486637
Am J Health Promot. 1997 Sep-Oct;12(1):8-10
pubmed: 10170438
JMIR Public Health Surveill. 2015 Apr 17;1(1):e3
pubmed: 27227126
MMWR Morb Mortal Wkly Rep. 2018 Mar 22;68(11):267-272
pubmed: 30897075
JMIR Res Protoc. 2019 Mar 26;8(3):e12050
pubmed: 30912750
JMIR Res Protoc. 2019 Jan 07;8(1):e10694
pubmed: 30617042
J Sex Res. 2014;51(4):390-409
pubmed: 24754360
J Int AIDS Soc. 2020 Jan;23(1):e25439
pubmed: 31909896
Curr HIV Res. 2013 Oct;11(7):520-7
pubmed: 24476355
Health Educ Res. 2014 Feb;29(1):147-57
pubmed: 23861481